[Federal Register: June 3, 2008 (Volume 73, Number 107)]
[Notices]
[Page 31699-31700]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr03jn08-52]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2008-N-0306]
Preparation for International Cooperation on Cosmetics
Regulations Meetings in Washington, DC; Public Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing a public
meeting entitled ``International Cooperation on Cosmetics Regulations
(ICCR)--Preparation for ICCR Meetings in Washington, DC'' to provide
information and receive comments on the International Cooperation on
Cosmetics Regulations (ICCR) as well as the upcoming meetings in
Washington, DC. The topics to be discussed are the topics for
discussion at the forthcoming ICCR steering committee meeting. The
purpose of the meeting is to solicit public input prior to the next
steering committee and expert working group meetings in Washington, DC,
the week of July 28, 2008, at which the action items from the first
ICCR meeting are to be discussed.
DATES: The meeting will be held on June 19, 2008, from 3 p.m. to 4:30
p.m. Send
[[Page 31700]]
registration information and requests to make a presentation by June
16, 2008.
ADDRESSES: The meeting will be held at 5600 Fishers Lane, 3rd fl.,
Chesapeake Conference Room, Rockville, MD 20857. For security reasons,
all attendees must preregister 3 days prior to the meeting and are
asked to arrive no later than 2:50 p.m. because attendees will be
escorted from the front entrance of 5600 Fishers Lane to the Chesapeake
Conference Room.
Comment Submissions: Submit written comments to the Divsion of
Dockets Management (HFA-305), Food and Drug Administration, 5630
Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments
to http://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Tammie Bell, Office of International
Programs, Food and Drug Administration, 5600 Fishers Lane, Rockville,
MD 20857, FAX: 301-827-0003, e-mail: Tammie.Bell2@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
The purpose of the multilateral framework on the ICCR is to pave
the way for the removal of regulatory obstacles to international trade
while maintaining the highest level of global consumer protection.
ICCR is a voluntary international group of cosmetics regulatory
authorities from the United States, Japan, the European Union, and
Canada. These regulatory authority members will enter into constructive
dialogue with their relevant cosmetics' industry trade associations.
Currently, the ICCR members are Health Canada; the European Commission
Directorate General for Enterprise and Industry; the Ministry of
Health, Labor, and Welfare of Japan; and the U.S. Food and Drug
Administration. All decisions made by the members of ICCR will be made
by consensus and will be compatible with the laws, policies, rules,
regulations, and directives of the respective administrations and
governments. Members will implement and/or promote actions or documents
within their own jurisdictions and seek convergence of regulatory
policies and practices. Successful implementation will require input
from stakeholders.
II. Registration and Requests for Oral Presentations
Send registration information (including name, title, firm name,
address, telephone, and fax number), written material and requests to
make oral presentations, to the contact person
(Tammie.Bell2@fda.hhs.gov) (see DATES).
If you need special accommodations due to a disability, please
contact Tammie Bell at least 7 days in advance.
Interested persons may present data, information, or views orally
or in writing, on issues pending at the public meeting. Oral
presentations from the public will be scheduled between approximately 4
p.m. and 4:30 p.m. Time allotted for oral presentations may be limited
to 10 minutes. Those desiring to make oral presentations should notify
the contact person (Tammie.Bell2@fda.hhs.gov) (see DATES) and submit a
brief statement of the general nature of the evidence or arguments they
wish to present, the names and addresses, phone number, fax, and e-mail
of proposed participants, and an indication of the approximate time
requested to make their presentation.
III. Transcripts
Please be advised that as soon as a transcript is available, it
will be accessible at http://www.fda.gov/ohrms/dockets/ac/acmenu.htm.
It may be viewed at the Division of Dockets Management (see ADDRESSES).
A transcript will also be available in either hardcopy or on CD-ROM,
after submission of a Freedom of Information request. Written requests
are to be sent to Division of Freedom of Information (HFI-35), Office
of Management Programs, Food and Drug Administration, 5600 Fishers
Lane, rm. 6-30, Rockville, MD 20857.
IV. Comments
Interested persons may submit written or electronic comments to the
Division of Dockets Management (see ADDRESSES). Submit a single copy of
electronic comments or two paper copies of any mailed comments, except
that individuals may submit one paper copy. Comments are to be
identified with the docket number found in brackets in the heading of
this document. Received comments may be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.
Please note that on January 15, 2008, the FDA Division of Dockets
Management Web site transitioned to the Federal Dockets Management
System (FDMS). FDMS is a Government-wide, electronic docket management
system. Electronic comments or submissions will be accepted by FDA only
through FDMS at http://www.regulations.gov.
V. Electronic Access
The agenda for the public meeting will be made available via the
internet at http://www.cfsan.fda.gov/~lrd/vidtel.html
Dated: May 28, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8-12338 Filed 6-2-08; 8:45 am]
BILLING CODE 4160-01-S